HIV Injections Keep Virus Suppressed Better Than Daily Pills: Lancet Study Finds

Long-acting HIV injections administered every eight weeks kept the virus suppressed more effectively than daily antiretroviral tablets among adolescents living with HIV, according to a clinical trial published in The Lancet. The 96-week study found confirmed viral rebound in just 1% of participants receiving injectable treatment, compared with 6% of those taking daily pills.

The findings from the LATA (Long-Acting Treatment in Adolescents) trial highlight the potential of long-acting injectable antiretroviral therapy to improve treatment adherence and maintain viral suppression among young people living with HIV.

HIV Injections Show Better Viral Suppression Over 96 Weeks

The LATA trial evaluated whether long-acting injectable HIV treatment could maintain viral suppression more effectively than standard daily oral medication among adolescents whose HIV was already well controlled.

After 96 weeks, researchers found that:

• 2 adolescents, or approximately 1%, in the injectable treatment group experienced confirmed viral rebound.
• 15 adolescents, or approximately 6%, in the daily tablet group experienced confirmed viral rebound.

The injectable regimen met the trial’s non-inferiority criteria and demonstrated statistical superiority over daily oral treatment for maintaining viral suppression.

These results suggest that long-acting injections may offer an effective maintenance treatment option for selected adolescents who have already achieved viral suppression with antiretroviral therapy.

What Was the LATA Trial?

The LATA trial was a randomised, open-label, multicentre study conducted across five clinical sites in Kenya, South Africa, Uganda and Zimbabwe.

The trial enrolled 476 adolescents aged 12 to 19 years who were living with HIV. Participants were randomly assigned to receive either long-acting injectable treatment or a standard daily oral antiretroviral regimen.

All participants had been taking oral HIV treatment for more than a year, had achieved viral suppression and had no history of previous treatment failure. Nearly all had acquired HIV at birth.

The researchers compared the ability of the two treatment approaches to maintain viral suppression over 96 weeks.

Which HIV Medicines Were Used in the Injections?

The injectable treatment combined two long-acting antiretroviral medicines: cabotegravir and rilpivirine.

Unlike conventional HIV treatment, which generally requires taking medication every day, the long-acting injectable regimen was administered at a clinic every eight weeks after an initial treatment schedule.

The comparison group continued taking a daily fixed-dose combination of dolutegravir, lamivudine and tenofovir disoproxil fumarate.

Both approaches are designed to suppress HIV replication. The difference is how the medicines are delivered and how frequently patients need to take or receive them.

What Does Viral Rebound Mean?

Viral rebound occurs when the amount of HIV in the blood rises after it has previously been suppressed by treatment.

In the LATA trial, confirmed viral rebound was defined using two consecutive viral-load measurements of at least 50 copies per millilitre, taken at least seven days apart.

Maintaining viral suppression is a central goal of HIV treatment. When antiretroviral therapy works effectively, it prevents the virus from multiplying extensively and helps protect the immune system.

Confirmed viral rebound can require further clinical assessment and may prompt doctors to review treatment adherence, resistance and other possible causes.

Why Long-Acting HIV Treatment Could Help Adolescents

Adolescents living with HIV can face particular challenges in maintaining daily treatment routines. Taking medication every day may be difficult because of school schedules, privacy concerns, stigma, bullying or the stress associated with managing a lifelong condition.

Long-acting injections may reduce some of these daily burdens by allowing patients to receive treatment at scheduled clinic visits rather than remembering to take pills every day.

In the LATA trial, 94% of adolescents receiving injectable treatment said the eight-weekly injections were much easier than taking daily medication.

This finding highlights the importance of considering treatment convenience and patient preferences alongside clinical effectiveness, particularly when designing HIV care for adolescents.

Injections Do Not Cure HIV

Although the findings are encouraging, long-acting injectable antiretroviral therapy is not a cure for HIV.

The medicines suppress viral replication and help maintain control of the infection, but they do not eliminate HIV from the body. Patients need to continue treatment according to their healthcare professional’s instructions.

The trial also focused on adolescents who had already achieved viral suppression with daily medication. Its findings should not automatically be applied to people with uncontrolled HIV, previous treatment failure or other clinical circumstances that were not represented in the study.

Patients should not stop, delay or switch their HIV medication without consulting their treating healthcare professional.

Access and Cost Remain Major Challenges

Despite the potential benefits, expanding access to long-acting injectable HIV treatment may be difficult in lower-resource settings.

The medicines are currently more expensive than many standard daily tablet regimens. Rilpivirine also requires refrigeration during storage and distribution, while injections must be administered by trained healthcare professionals.

These requirements can create logistical challenges for health systems, particularly in areas where clinics have limited staffing, cold-chain infrastructure or resources for frequent patient follow-up.

Researchers have therefore highlighted the need to improve affordability and access if long-acting treatment is to reach more adolescents and other populations who could benefit from it.

What the Findings Mean for HIV Treatment

The LATA trial adds important evidence to the growing research on long-acting injectable antiretroviral therapy.

For adolescents who have already achieved viral suppression, injections administered every eight weeks may provide an alternative to daily tablets while helping maintain treatment effectiveness.

The findings also reinforce the importance of tailoring HIV treatment to the needs of individual patients. Treatment decisions must consider clinical eligibility, patient preference, access to injections, the ability to attend scheduled appointments and the availability of ongoing monitoring.

Conclusion

The LATA trial found that long-acting HIV injections administered every eight weeks maintained viral suppression more effectively than daily tablets among adolescents with already-controlled HIV. After 96 weeks, confirmed viral rebound occurred in approximately 1% of participants receiving injections, compared with 6% of those taking daily oral treatment.

The results suggest that long-acting injectable therapy could be a valuable maintenance option for selected adolescents living with HIV. However, the treatment does not cure HIV, and affordability, clinic infrastructure and eligibility remain important considerations for wider use.

SEO Details

Primary Keyword: long-acting HIV injections

Secondary Keywords: HIV injections vs daily pills, LATA trial, HIV viral suppression, cabotegravir and rilpivirine, injectable HIV treatment, HIV treatment in adolescents, antiretroviral therapy, viral rebound, long-acting HIV medication

Meta Title: HIV Injections vs Daily Pills: Lancet Study Finds Better Viral Suppression

Meta Description: The Lancet’s LATA trial found HIV injections every eight weeks maintained viral suppression better than daily pills among adolescents over 96 weeks.

Research Reference: Bwakura-Dangarembizi M, et al. Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial. The Lancet. Published September 17, 2026. DOI: 10.1016/S0140-6736(26)01537-0.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. HIV treatment should be selected and monitored by a qualified healthcare professional. Do not stop or change antiretroviral medication without medical guidance.